This Phase I contract proposal will evaluate and identify markers associated with prostate cancer progenitor stem cells, that differentiate these cells from adult tissue stem cells and benign prostate progenitor cells. The eventual goal of this work would be to develop a high throughput blood-based… More

The goal of this proposal is to develop directed energy transfer methods for imaging, tissue ablation and release of therapeutic modalities targeted to the vasculature of prostate cancer. The platform technology is a freeze-dried human platelet (Stasix par ticles) that contains super paramagnetic… More

DESCRIPTION (provided by applicant): Benign Prostatic Hyperplasia/Hypertrophy is a major health problem in the United States, with one-in-three men having urologic problems. Currently available treatment modalities include alpha-blockers that do not affect the underlying pathologic process, and… More

DESCRIPTION (provided by applicant): AndroBioSys, Inc. is dedicated to the development of human tissue-based in vivo tools capable of selecting better targeted agents for clinical trials by improved preclinical testing. AndroBioSys has developed the techno logy for reproducible implantation of… More

The goal of this Phase II proposal is to develop directed energy transfer methods for imaging, tissue ablation and release of therapeutic modalities targeted to the vasculature of prostate cancer. The platform technology is a freeze-dried human platelet (Stasix particles) that contains super… More

The technical objectives of this Phase II project are to identify unique biomarkers and produce molecular, antibody and peptide reagents that are specific for human prostate cancer progenitor stem cells. We propose to utilize the information from the Phase I award and subsequent research to develop… More